ライブ
Endpoints News#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetesClinical OMICsBlood-Based Risk Score Could Enable Earlier Lung Cancer PreventionClinical OMICsMicroglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to DementiaEndpoints NewsIn Washington, biotech's China hawks are winning the conversationClinical OMICsUniversal Coronavirus Vaccine Could Provide Protection Against Future StrainsEndpoints NewsIndustry seeks more clarity on commissioner's voucher programBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 4, 2026BioWorldBioWorld and Nasdaq stock indicesEndpoints NewsHouse committee directs FDA to speed up IND sign-off processFierceBiotechExecutive Interviews at Fierce Biotech Week 2026BioWorldBiopharma money raised by month in 2026 (US$M)
Illumina 2026年2月16日

Illumina: Weak Backlog Support and Rising Competitive Pressures Undermine 2026 Outlook, Justifying Sell Rating - TipRanks

Illumina: Weak Backlog Support and Rising Competitive Pressures Undermine 2026 Outlook, Justifying Sell Rating - TipRanks

原文
本文は利用できません。元の情報源をご確認ください。